The BTK Inhibitor CC-292 shows activity in Mantle Cell Lymphoma and synergizes with Lenalidomide and NIK Inhibitors depending on NFκB mutational status
Ontology highlight
ABSTRACT: Mantle Cell lymphoma (MCL) were treated with the BTK inhibitor 1mM CC-292 for 48h We used microarrays to uncover the mechanisms underlying CC-292 activity in Mantle Cell lymphoma (MCL)
ORGANISM(S): Homo sapiens
PROVIDER: GSE94328 | GEO | 2017/09/01
SECONDARY ACCESSION(S): PRJNA369382
REPOSITORIES: GEO
ACCESS DATA